Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 2, 2007, Pages 125-133

  Xu, Jing Xian ^a   Hoshida, Yoshihiko ^a   Hongyo, Tadashi ^a   Sasaki, Toru ^a   Miyazato, Hajime ^a   Tomita, Yasuhiko ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bak gene; Lymphoproliferative disorder; Methotrexate; p53 gene; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; PROTEIN BAK; PROTEIN P53;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TISSUE SECTION;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; MUTATION; PHENOTYPE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845679062     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0152-2     Document Type: Article

References (40)

1. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L (2003) Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 48:1543-1550
2. Chen PM, Chiou TJ, Hsieh RK, Fan FS, Chu CJ, Lin CZ, Chiang H, Yen CC, Wang WS, Liu JH (1999) p53 gene mutations and rearrangements in non-Hodgkin's lymphoma. Cancer 85:718-724
3. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC (1995) Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374:733-736
4. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221
5. Edwards RH, Raab-Traub N (1994) Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphoma. J Virol 68:1309-1315
6. Ellman MH, Hurwitz H, Thomas C, Kozloff M (1991) Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18:1741-1743
7. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse HJ, Kenney SC (2004) Reactivation of latent Epstein-Barr virus by methotrexate. A potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 96:1691-1702
8. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R (1991) p53 mutations in human lymphoid malignancies association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417
9. Gaidano G, Carbone A, Dalla-Favera R (1998) Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Natl Cancer Inst Monogr 23:95-100
10. Georgescu L, Paget SA (1999) Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf 20:475-487
11. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307-311
12. Hanna N, Fidler IJ (1980) Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 65:801-809
13. Harris NL, Swerdlow SH (2001) Methotrexate-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL and Stein H et al (eds) Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues, World Health Organization Classification of Tumours. IARC Press, Lyon pp 270-271
14. Hollstein M, Sidransky D, Vogelstein B, Harris SR (1991) p53 mutations in human cancers. Science 253:49-53
15. Hongyo T, Buzard GS, Calvert RJ, Weghorst CM (1993) 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single strand conformation polymorphism analyses. Nucleic Acids Res 21:3637-3642
16. Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K, Nomura T (1998) Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer Res 58:1105-1107
17. Hoshida Y, Hongyo T, Nakatsuka S, Nishiu M, Takakuwa T, Tomita Y, Nomura T, Aozasa K (2002) Gene mutations in lymphoproliferative disorders of T and NK/T cell phenotypes developing in renal transplant patients. Lab Invest 82:257-264
18. Hoshida Y, Tomita Y, Zhiming D, Yamauchi A, Nakatsuka S, Kurasono Y, Arima Y, Tsudo M, Shintaku M, Aozasa K (2004) Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 108:443-449
19. Hoshida Y, Hongyo T, Xu JX, Sasaki T, Tomita Y, Nomura T, Aozasa K (2005) TP53 gene mutation is an unfavorable prognostic factor for malignant lymphomas in autoimmune disease. Oncology 69:175-183
20. Hsu S-M, Raine L, Fanger H (1981) The use of antiavidin antibody and avidin-biotin-peroxidase complex in immuno-peroxidase technics. Am J Clin Pathol 75:816-821
21. Imamura J, Miyoshi I, Koeffler HP (2002) p53 in hematologic malignancy. Blood 84:2412-2421
22. Isomaki HA, Hakulinen T, Joutsenlahti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31:691-696
23. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics, tumours of haematopoietic and lymphoid tissues, World Health Organization classification of tumours. IARC Press, Lyon
24. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Amer Statist Assoc 53:457-481
25. Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD (1997) Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90:4078-4091
26. Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, Nagasawa Y, Nakahara M, Kanayama S, Matsuzawa Y (2000) Mutations of the Bak gene in human gastric and colorectal cancers. Cancer Res 60:4328-4330
27. Levine AJ, Momand J, Finley CA (1991) The p53 tumor suppressor gene. Nature 351:453-456
28. Li T, Hongyo T, Syaifudin M, Nomura T, Dong Z, Shingu N, Kojya S, Nakatsuka S, Aozasa K (2000) Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 80:493-499
29. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) Investigators of the Club Rhumatismes et Inflammation: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99:3909-3915
30. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753-1757
31. Newcomb EW (1995) P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 17:211-221
32. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39
33. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14:1943-1949
34. Symmons DP (1985) Neoplasms of the immune system in rheumatic arthritis. Am J Med 78:22-28
35. Takeuchi O, Fisher J, Suh H, Harada H, Malynn BA, Korsmeyer S (2005) Essential role of BAX, BAK in B cell homeostasis and prevention of autoimmune disease. Proc Natl Acad Sci USA 102:11272-11277
36. Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497-502
37. Wani KM, Huilgol NG, Hongyo T, Shah K, Chatterjee N, Nair CK, Nomura T (2003) Genetic alterations in the coding region of the Bak gene in uterine cervical cancinoma. Br J Cancer 88:1584-1586
38. Weiss LM, Chen Y-Y, Liu XF, Shibata D (1991) Epstein-Barr virus and Hodgkin's disease: a correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 139:1259-1265
39. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609
40. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS (2002) Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 99:10025-10030